Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study on the Safety and the Efficacy of Personalized Neoantigen-primed Dendritic Cell Vaccines for Refractory Lung Cancer

NCT03871205 is registered in ClinicalTrials.gov with Shenzhen People's Hospital as lead sponsor.

NCT NCT03871205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03871205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study on the Safety and the Efficacy of Personalized Neoantigen-primed Dendritic Cell Vaccines for Refractory Lung Cancer
Lead sponsor
Shenzhen People's Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
April 1, 2019
Completion date
December 30, 2020
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, carcinoma, small cell lung